EPL Attending the 37th American College of Toxicology (ACT) Annual Meeting
EPL is pleased to announce that we are a Gold Level sponsor of the American College of Toxicology (ACT) Annual Meeting in Baltimore, MD. We will have an exhibit in booth #400. EPL’s wholly owned subsidiary, Aclairo Pharmaceutical Development Group is also a Gold Level sponsor and will be sponsoring the Opening Reception.
Dr. Paul Snyder from EPL will be serving as Chair for the Symposium, “Current Topics in Neurodegenerative Disease Pathogenesis and Drug Development.” This session will be held on Wednesday, November 9, 2016 from 9:00am – 12:00pm. EPL will be co-sponsoring this symposium along with Biogen. Symposium #16 will include a broad array of current topics in neurodegenerative disease pathogenesis and drug development. These will include review of current concepts in disease pathogenesis (protein misfolding and the spreading hypothesis), examples of development challenges (amyloid related imaging abnormalities; ARIA-E, ARIA-H associated with antibody therapeutics), and novel therapeutic approaches such as the intrathecally administered antisense oligonucleotides.
EPL is also co-sponsoring a symposium along with PreClinical Research Services entitled, “Why Do Promising Therapies Stall in Development and How Can We Move Them Forward?” Symposium #8 will be held Monday, November 7, 2016 from 2:00pm – 5:00pm. This session which will focus on reasons that molecules fail to progress to market and the principles of risk-benefit decisions that can drive the molecule through development.
Additional information about the courses to be held at the 2016 ACT Annual Meeting can be found at the ACT 2016 Annual Meeting website.